References
- Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6
- European Medicines Agency. Imfinzi, INN-durvalumab. 2020. [cited 30 Nov 2020]. Available at: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf
- Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017; 7: 5532. doi: 10.1038/s41598-017-06002-8
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64. doi: 10.1038/nrc3239
- Sun MM, Levinson RD, Filipowicz A, Anesi S, Kaplan HJ, Wang W, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 2020; 28: 217-27. doi: 10.1080/09273948.2019.1577978
- Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm 2021; 29: 20311. doi: 10.1080/09273948.2020.1781902
- Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm 2021; 29: 1585-90. doi: 10.1080/09273948.2020.17660828
- Andrade AR, Moll-Udina A, Martin R, Cilveti E, Subirà O, Disfetano L, et al. Retinal vasculitis secondary to durvalumab. Case Rep Ophthalmol 2020; 11: 161-6. doi: 10.1159/000507609
- Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthal Inflamm Infect 2016; 6: 14. doi: 10.1186/s12348-016-0082-3
- Aaberg MT, Aaberg TM. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep 2017; 11: 348-51. doi: 10.1097/ICB.0000000000000368
- Wang W, Lam WC, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 2019; 68: 85-95. doi: 10.1007/s00262-018-2260-7
- Reid G, Lorigan P, Heimann H, Hovan M. et al. Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. Ocul Immunol Inflamm 2019; 27: 1012–15. doi: 10.1080/09273948.2018.1459733
- Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E. Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol 2019; 67: 2075-7. doi: 10.4103/ijo.IJO_1161_19
- Kim YJ, Lee JS, Lee J, Lee SC, Kim TI, Byeon SH, et al. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother 2020; 69: 2241-52. doi: 10.1007/s00262-020-02635-3
- Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 2020; 20: 252. doi: 10.1186/s12886-020-01519-5
- Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer 2021; 9: e002119. doi: 10.1136/jitc-2020-002119
- Carrera W, Baartman BJ, Kosmorsky G. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer. Neuro-Ophthalmol 2017; 41: 140-3. doi: 10.1080/01658107.2017.1291686
- Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm 2020; 28: 854-9. doi: 10.1080/09273948.2019.1583347
- Sabini E, Sframeli A, Marinò M. A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab. J Endocrinol Invest 2018; 41: 877-8. doi: 10.1007/s40618-018-0906-0
- Yang W, Li H, Chen PW, Chen HX, Murray J, Sen HN, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009; 50: 273-80. doi: 10.1167/iovs.08-2397
- Francis JH, Berry D, Abramson DH, Barker CA, Bergstrom C, Demirci H, et al. Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition. Ophthalmology 2020; 127: 240-8. doi: 10.1016/j.ophtha.2019.09.018
- Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuroophthalmol 2021; 41: 519-30. doi; 10.1097/WNO.0000000000001148
- Gordon L, Dinkin M. Paraneoplastic syndromes in neuro-ophthalmology. Continuum (Minneap Minn) 2019; 25: 1401-21. doi: 10.1212/CON.0000000000000788.
- Xu Q, Du W, Zhou H, Zhang X, Liu H, Song H, et al. Distinct clinical characteristics of paraneoplastic optic neuropathy. Br J Ophthalmol 2019; 103: 797-801. doi: 10.1136/bjophthalmol-2018-312046
- Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54: 38-50. doi: 10.1002/ana.10587
- Adamus G, Champaigne R, Yang S. Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy. Clin Immunol 2020; 210: 108317. doi: 10.1016/j.clim.2019.108317
- Yagyu K, Ueda T, Miyamoto A, Uenishi R, Matsushita H, Tanaka T. Cancerassociated retinopathy with neuroendocrine combined large-cell lung carcinoma and adenocarcinoma. Intern Med 2019; 58: 3289-94. doi: 10.2169/internalmedicine.2313-18
- Hoogewoud F, Butori P, Blanche P, Brézin AP. Cancer-associated retinopathy preceding the diagnosis of cancer. BMC Ophthalmol 2018; 18: 285. doi: 10.1186/s12886-018-0948-2
- Makiyama Y, Kikuchi T, Otani A, Oishi A, Guo C, Nakagawa S, et al. Clinical and immunological characterization of paraneoplastic retinopathy. Invest Ophthalmol Vis Sci 2013; 54: 5424-31. doi: 10.1167/iovs.13-11868
- Pepple KL, Cusick M, Jaffe GJ, Mruthyunjaya P. SD-OCT and autofluorescence characteristics of autoimmune retinopathy. Br J ophthalmol 2013; 97: 13944. doi: 10.1136/bjophthalmol-2012-302524
- Lee KM, Woo SJ, Hwang JM. Factors associated with visual field defects of optic disc. PLoS One 2018; 13: e0196001. doi: 10.1371/journal.pone.0196001
- Casado A, Rebolleda G, Guerrero L, Leal M, Contreras I, Oblanca N, et al. Measurement of retinal nerve fiber layer and macular ganglion cell–inner plexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1653-60. doi: 10.1007/s00417-014-2773-5
- Coscas G, De Benedetto U, Coscas F, Li Calzi CI, Vismara S, Roudot-Thoraval F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013; 229: 32-7. doi: 10.1159/000342159